Answer
Gefitinib selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, targeting tumours with activating mutations in this receptor; no clinically relevant activity has been shown in known EGFR mutation-negative tumours.
Sources for this answer
- Iressa 250mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 18Document updated
Sources checked